Home>Biopharmaceutical Manufacturing>BioReliance® Product Characterization Services

BioReliance® Product Characterization Services


Ask us a question
Cell Line Development Interlot & Biosimilar Comparability Lot Release & Stability Process & Product Impurities


Assay Packages
Interlot and Biosimilar Comparability

Monoclonal antibodies (mAbs) are highly complex biomolecules easily affected by changes within the biopharmaceutical manufacturing process. Something as simple as a temperature fluctuation can produce a change in higher order structure (HOS) that renders the mAb less active or inactive.

Whether your mAb is an original product or a biosimilar, our comparability studies are designed to ensure robust and reproducible mAb production, and include:

  • Comparability between a biosimilar and an original product
  • Comparability between different production facilities
Ideal during:
Discovery
Pre-Clinical
Phase I
Phase II
Phase III
Manufacturing

Assay families that satisfy testing needs include:


  • Molecular weight comparison

    Molecular weight is a major indicator of mAb identity, influenced by the nature of the light and heavy chains as well as by post-translational modifications (PTM). Providing an indication of similarity to reference material, intact mass (IM) analysis is supported by studies to evaluate the molecular weight of individual chains, or to assess levels of glycosylation.

  • Amino acid analysis

    Used to determine the amino acid composition of a mAb, amino acid analysis is a popular way to establish product identity. It is often performed alongside an extinction coefficient measurement, a method routinely employed to establish titer between different productions.

  • Sequence mapping

    Sequence mapping varies considerably in its level of complexity. To gain an indication of the identity of your mAb, comparison of simple, single enzyme peptide maps may be sufficient, whereas to better inform product engineering, N- or C-terminal sequencing may be performed. Mass spectrometry provides additional structural information.

  • Higher order structure (HOS) comparison

    Many factors influence HOS – the 3D structure of a mAb – ranging from the choice of cell line for mAb production to bioprocessing conditions such as temperature, pH and light exposure. Hydrogen deuterium exchange mass spectrometry (HDX-MS) is a method that allows for a detailed insight into the tertiary structure of a mAb.

  • Modification analysis

    Many different post-translational modifications can occur during the mAb manufacturing process, which are are greatly influenced by process parameters such as media, temperature, etc. To produce a consistent product, it is important these modifications are reproduced during every round of mAb synthesis. Modification analysis includes disulfide bridge mapping, and evaluation of glycan basic structure. It is also wise to quantify sialylation, since sialic acid can have a negative effect on your mAb.

  • Product purity / impurity testing

    The presence of impurities in your mAb product can present a serious risk, preventing regulatory approval from being granted. Size and charge variants can be identified using techniques such as dynamic light scattering (DLS) and UHPLC ion exchange. It is also wise to monitor the presence of residuals such as detergent, surfactant, protein or DNA.

  • Potency / binding

    The affinity of your mAb for its target is key to its clinical efficacy and a critical attribute that needs to be assessed in early process development. Measurement of binding using Surface Plasmon Resonance (SPR) can provide rapid determination of binding, with the added benefit of kinetic information regarding association and disassociation rates which is more informative than measurement of affinity using ELISA. Beyond Fab mediated biological activity, the success of many mAb therapeutics is dependent on biological activities mediated by the Fc region, where applicable, involving recruitment of immune system cells and components. To thoroughly evaluate the potency of your mAb, relevant binding and cell-based assays should be implemented early in the drug development process to understand the biological functionality of all regions of the mAb molecule.



Hear from Our Experts

Get insight into topics that directly impact your success to clinic. Learn more from our white papers, videos, webinars, and posters.

Knowledge Center

Contact Us

Contact our product characterization experts to discuss your specialized needs and take the next step to securing the future of your biotherapy.

Ask Us a Question Connect with Us on LinkedIn